Controversial issues in Gleason and International Society of Urological Pathology (ISUP) prostate cancer grading: proposed recommendations for international implementation

Imagem de Miniatura
Arquivos
art_SRIGLEY_Controversial_issues_in_Gleason_and_International_Society_of_2019.PDF (1.98 MB)
Citações na Scopus
50
Tipo de produção
article
Data de publicação
2019
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE BV
Autores
SRIGLEY, John R.
DELAHUNT, Brett
SAMARATUNGA, Hemamali
BILLIS, Athanase
CHENG, Liang
CLOUSTON, David
EVANS, Andrew
FURUSATO, Bungo
KENCH, James
Citação
PATHOLOGY, v.51, n.5, p.463-473, 2019
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
The Gleason Grading system has been used for over 50 years to prognosticate and guide the treatment for patients with prostate cancer. At consensus conferences in 2005 and 2014 under the guidance of the International Society of Urological Pathology (ISUP), the system has undergone major modifications to reflect modern diagnostic and therapeutic practices. The 2014 consensus conference yielded recommendations regarding cribriform, mucinous, glomeruloid and intraductal patterns, the most significant of which was the removal of any cribriform pattern from Gleason grade 3. Furthermore, a Gleason score grouping system was endorsed which consisted of five grades where Gleason score 6 (3+3) was classified as grade 1 which better reflected the mostly indolent behaviour of these tumours. Another issue discussed at the meeting and subsequently endorsed was that in Gleason score 7 cases, the percentage pattern 4 should be recorded. This is especially important in situations where modern active surveillance protocols expand to include men with low volume pattern 4. While major progress was made at the conference, several issues were either not resolved or not discussed at all. Most of these items relate to details of assignment of Gleason score and ISUP grade in specific specimen types and grading scenarios. This detailed review looks at the 2014 ISUP conference results and subsequent literature from an international perspective and proposes several recommendations. The specific issues addressed are percentage pattern 4 in Gleason score 7 tumours, percentage patterns 4 and 5 or 4/5 in Gleason score 8-10 disease, minor (<= 5%) high grade patterns when either 2 or 3 patterns are present, level of reporting (core, specimen, case), dealing with grade diversity among site (highest and composite scores) and reporting scores in radical prostatectomy specimens with multifocal disease. It is recognised that for many of these issues, a strong evidence base does not exist, and further research studies are required. The proposed recommendations mostly reflect consolidated expert opinion and they are classified as established if there was prior agreement by consensus and provisional if there was no previous agreement or if the item was not discussed at prior consensus conferences. For some items there are reporting options that reflect the local requirements and diverse practice models of the international urological pathology community. The proposed recommendations provide a framework for discussion at future consensus meetings.
Palavras-chave
Prostate adenocarcinoma, grading, ISUP grade, Gleason, International Society of Urological Pathology
URI
https://observatorio.fm.usp.br/handle/OPI/32970
Referências
  1. Amin MB, 2014, ARCH PATHOL LAB MED, V138, P1387, DOI 10.5858/arpa.2014-0219-SA
  2. Amin MB, 2017, AJCC CANC STAGING MA
  3. Arora R, 2004, CANCER-AM CANCER SOC, V100, P2362, DOI 10.1002/cncr.20243
  4. Baras AS, 2017, HUM PATHOL, V63, P27, DOI 10.1016/j.humpath.2016.12.008
  5. Berney DM, 2016, BRIT J CANCER, V114, P1078, DOI 10.1038/bjc.2016.86
  6. Berney DM, 2014, HISTOPATHOLOGY, V64, P405, DOI 10.1111/his.12284
  7. Chan TY, 2000, UROLOGY, V56, P823, DOI 10.1016/S0090-4295(00)00753-6
  8. Danneman D, 2015, BJU INT, V115, P248, DOI 10.1111/bju.12671
  9. Delahunt B, 2015, PATHOLOGY, V47, P520, DOI 10.1097/PAT.0000000000000318
  10. Delahunt B, 2013, AM J SURG PATHOL, V37, P1490, DOI 10.1097/PAS.0b013e318299f0fb
  11. Delahunt B, 2012, HISTOPATHOLOGY, V60, P75, DOI 10.1111/j.1365-2559.2011.04003.x
  12. Descazeaud A, 2005, EUR UROL, V48, P911, DOI 10.1016/j.eururo.2005.07.011
  13. Egevad L, 2002, J UROLOGY, V168, P509, DOI 10.1016/S0022-5347(05)64669-1
  14. Egevad L, 2017, PROSTATE CORE NEEDLE
  15. Egevad L, 2017, PROSTATE CANC RADICA
  16. Egevad L, 2019, PATHOLOGY, V51, P11, DOI 10.1016/j.pathol.2018.10.003
  17. Egevad L, 2016, AM J SURG PATHOL, V40, P858, DOI 10.1097/PAS.0000000000000642
  18. Egevad L, 2011, HISTOPATHOLOGY, V59, P1011, DOI 10.1111/j.1365-2559.2011.03925.x
  19. Epstein JI, 2005, AM J SURG PATHOL, V29, P1228, DOI 10.1097/01.pas.0000173646.99337.b1
  20. Epstein JI, 1998, AM J SURG PATHOL, V22, P1435, DOI 10.1097/00000478-199812000-00001
  21. Epstein JI, 2017, AM J SURG PATHOL, V41, pE1, DOI 10.1097/PAS.0000000000000820
  22. Epstein JI, 2016, AM J SURG PATHOL, V40, P244, DOI 10.1097/PAS.0000000000000530
  23. Glaessgen A, 2004, J UROLOGY, V171, P664, DOI 10.1097/01.ju.0000108198.98598.00
  24. Glaessgen A, 2002, J UROLOGY, V168, P2006, DOI 10.1097/01.ju.0000034255.95952.df
  25. Gleason DF, 1977, UROLOGIC PATHOLOGY P, P171
  26. GLEASON DONALD F., 1966, CANCER CHEMO THERAP REP, V50, P125
  27. Grogan J, 2017, BJU INT, V120, P651, DOI 10.1111/bju.13857
  28. Haffner MC, 2013, J CLIN INVEST, V123, P4918, DOI 10.1172/JCI70354
  29. Huang CC, 2014, VIRCHOWS ARCH, V464, P589, DOI 10.1007/s00428-014-1557-y
  30. Isbarn H, 2009, EUR UROL, V55, P394, DOI 10.1016/j.eururo.2008.08.015
  31. Jang WS, 2017, PROSTATE CANCER P D, V20, P93, DOI 10.1038/pcan.2016.55
  32. Kato M, 2019, MODERN PATHOL, V32, P122, DOI 10.1038/s41379-018-0121-8
  33. Kench JG, 2019, VIRCHOWS ARCH
  34. Kunju LP, 2009, HUM PATHOL, V40, P558, DOI 10.1016/j.humpath.2008.07.020
  35. Lindberg J, 2015, EUR UROL, V67, P819, DOI 10.1016/j.eururo.2014.09.006
  36. Lindberg J, 2013, EUR UROL, V63, P347, DOI 10.1016/j.eururo.2012.03.050
  37. Loeb S, 2016, EUR UROL, V69, P1135, DOI 10.1016/j.eururo.2015.11.036
  38. MCNEAL JE, 1990, CANCER, V66, P1225, DOI 10.1002/1097-0142(19900915)66:6<1225::AID-CNCR2820660624>3.0.CO;2-X
  39. Moch H, 2016, WHO CLASSIFICATION T
  40. Mohler JL, 2019, J NATL COMPR CANC NE, V17, P479, DOI 10.6004/jnccn.2019.0023
  41. Morash C, 2015, CUAJ-CAN UROL ASSOC, V9, P171, DOI 10.5489/cuaj.2806
  42. Pan CC, 2000, AM J SURG PATHOL, V24, P563, DOI 10.1097/00000478-200004000-00011
  43. Paner GP, 2017, PROTOCOL EXAMINATION
  44. Partin AW, 1997, JAMA-J AM MED ASSOC, V277, P1445, DOI 10.1001/jama.277.18.1445
  45. Poulos CK, 2005, MODERN PATHOL, V18, P228, DOI 10.1038/modpathol.3800302
  46. Qi R, 2017, CAN J UROL, V24, P8982
  47. Sadimin ET, 2016, AM J SURG PATHOL, V40, P1686, DOI 10.1097/PAS.0000000000000714
  48. Sakr WA, 2000, UROLOGY, V56, P730, DOI 10.1016/S0090-4295(00)00791-3
  49. Samaratunga H, 2015, PATHOLOGY, V47, P515, DOI 10.1097/PAT.0000000000000315
  50. Samaratunga H, 2011, MODERN PATHOL, V24, P6, DOI 10.1038/modpathol.2010.178
  51. Sauter G, 2016, EUR UROL, V69, P592, DOI 10.1016/j.eururo.2015.10.029
  52. Shariat SF, 2008, CANCER-AM CANCER SOC, V113, P3075, DOI 10.1002/cncr.23908
  53. Srigley JR, 2014, PATHOLOGY, V46, P579, DOI 10.1097/PAT.0000000000000183
  54. Srigley JR, 2013, AM J SURG PATHOL, V37, P1469, DOI 10.1097/PAS.0b013e318299f2d1
  55. Srigley JR, 2009, ARCH PATHOL LAB MED, V133, P1568, DOI 10.1043/1543-2165-133.10.1568
  56. Srigley JR, 2000, ARCH PATHOL LAB MED, V124, P1034
  57. Stamey TA, 2000, J UROLOGY, V163, P1155, DOI 10.1016/S0022-5347(05)67713-0
  58. Stamey TA, 1999, JAMA-J AM MED ASSOC, V281, P1395, DOI 10.1001/jama.281.15.1395
  59. Stephenson AJ, 2006, JNCI-J NATL CANCER I, V98, P715, DOI 10.1093/jnci/djj190
  60. Tolonen TT, 2011, BMC UROL, V11, DOI 10.1186/1471-2490-11-21
  61. van der Kwast TH, 2011, MODERN PATHOL, V24, P16, DOI 10.1038/modpathol.2010.156
  62. van Oort IM, 2005, EUR UROL, V48, P572, DOI 10.1016/j.eururo.2005.06.003

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCG
Artigos e Materiais de Revistas Científicas - LIM/55
Artigos e Materiais de Revistas Científicas - ODS/03